Vertex Pharmaceuticals Shows Potential in Developing Therapies, But Faces Hedge Fund Disinterest

PGIM Jennison Health Sciences Fund’s first quarter 2025 investor letter showed a loss in value, underperforming the S&P 1500 Health Care Index. Biotechnology and providers outperformed, while life sciences tools declined. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had a one-month return of 1.75% and closed at $459.41 per share on July 7, 2025.

The fund’s letter highlighted Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as a leader in cystic fibrosis treatments. The company has a market capitalization of $117.975 billion. Vertex Pharmaceuticals is developing therapies for CF and acute pain, with a strong pipeline in genetically driven diseases. The company has performed well in clinical trials and revenue estimates.

Despite potential, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not among the 30 most popular stocks among hedge funds. Only 60 hedge fund portfolios held Vertex at the end of the first quarter. Alternative investment stocks, particularly in AI, are seen as offering higher returns in a shorter timeframe. Consider undervalued AI stocks for potential gains.

Read more at Yahoo Finance: Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?